See how Novartis is responding to Coronavirus (COVID-19)
This site is intended for UK healthcare professionals only. If you are a member of the public, please click here
_
Dr Paul Nathan presents the data on the use of Tafinlar (dabrafenib) + Mekinist (trametinib) in the adjuvant setting for management of adult patients with BRAF V600 stage III melanoma, following complete resection. Filmed August 2018.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]
